Pfizer EBIT Margin 2010-2023 | PFE
Current and historical EBIT (Earnings Before Interest & Taxes) margin for Pfizer (PFE) over the last 10 years. The current EBIT profit margin for Pfizer as of December 31, 2023 is .
| Pfizer EBIT Margin Historical Data |
| Date |
TTM Revenue |
TTM EBIT |
EBIT Margin |
| 2023-12-31 |
$58.50B |
$0.22B |
0.38% |
| 2023-09-30 |
$68.54B |
$9.21B |
13.44% |
| 2023-06-30 |
$77.94B |
$21.59B |
27.69% |
| 2023-03-31 |
$92.95B |
$31.88B |
34.30% |
| 2022-12-31 |
$100.33B |
$34.94B |
34.83% |
| 2022-09-30 |
$99.88B |
$33.55B |
33.59% |
| 2022-06-30 |
$101.28B |
$30.76B |
30.37% |
| 2022-03-31 |
$92.43B |
$24.15B |
26.12% |
| 2021-12-31 |
$81.29B |
$19.43B |
23.91% |
| 2021-09-30 |
$68.88B |
$17.15B |
24.89% |
| 2021-06-30 |
$55.12B |
$13.45B |
24.39% |
| 2021-03-31 |
$46.08B |
$9.91B |
21.51% |
| 2020-12-31 |
$41.65B |
$8.25B |
19.81% |
| 2020-09-30 |
$32.07B |
$2.62B |
8.17% |
| 2020-06-30 |
$34.47B |
$3.13B |
9.08% |
| 2020-03-31 |
$37.87B |
$5.32B |
14.06% |
| 2019-12-31 |
$40.91B |
$6.71B |
16.40% |
| 2019-09-30 |
$40.22B |
$5.62B |
13.98% |
| 2019-06-30 |
$40.84B |
$6.43B |
15.74% |
| 2019-03-31 |
$41.04B |
$6.14B |
14.95% |
| 2018-12-31 |
$40.83B |
$5.67B |
13.89% |
| 2018-09-30 |
$53.37B |
$14.00B |
26.22% |
| 2018-06-30 |
$53.24B |
$13.90B |
26.10% |
| 2018-03-31 |
$52.67B |
$13.66B |
25.94% |
| 2017-12-31 |
$52.55B |
$13.72B |
26.11% |
| 2017-09-30 |
$52.47B |
$13.17B |
25.10% |
| 2017-06-30 |
$52.35B |
$12.53B |
23.93% |
| 2017-03-31 |
$52.60B |
$12.26B |
23.32% |
| 2016-12-31 |
$52.82B |
$12.15B |
22.99% |
| 2016-09-30 |
$53.24B |
$12.22B |
22.96% |
| 2016-06-30 |
$52.29B |
$12.56B |
24.02% |
| 2016-03-31 |
$50.99B |
$12.68B |
24.86% |
| 2015-12-31 |
$48.85B |
$11.82B |
24.20% |
| 2015-09-30 |
$47.92B |
$12.14B |
25.33% |
| 2015-06-30 |
$48.20B |
$12.46B |
25.85% |
| 2015-03-31 |
$49.12B |
$12.82B |
26.09% |
| 2014-12-31 |
$49.61B |
$13.25B |
26.71% |
| 2014-09-30 |
$50.05B |
$14.15B |
28.26% |
| 2014-06-30 |
$50.33B |
$14.45B |
28.71% |
| 2014-03-31 |
$50.53B |
$14.78B |
29.26% |
| 2013-12-31 |
$51.58B |
$15.18B |
29.44% |
| 2013-09-30 |
$50.88B |
$14.70B |
28.90% |
| 2013-06-30 |
$51.19B |
$14.46B |
28.25% |
| 2013-03-31 |
$52.18B |
$15.04B |
28.82% |
| 2012-12-31 |
$54.66B |
$15.26B |
27.93% |
| 2012-09-30 |
$53.25B |
$14.62B |
27.45% |
| 2012-06-30 |
$56.90B |
$14.96B |
26.29% |
| 2012-03-31 |
$59.42B |
$14.12B |
23.76% |
| 2011-12-31 |
$61.04B |
$13.97B |
22.88% |
| 2011-09-30 |
$65.06B |
$13.94B |
21.43% |
| 2011-06-30 |
$64.44B |
$13.62B |
21.13% |
| 2011-03-31 |
$65.09B |
$13.80B |
21.19% |
| 2010-12-31 |
$65.17B |
$13.41B |
20.58% |
| 2010-09-30 |
$65.50B |
$11.49B |
17.54% |
| 2010-06-30 |
$61.13B |
$11.85B |
19.39% |
| 2010-03-31 |
$54.98B |
$10.77B |
19.60% |
| 2009-12-31 |
$49.27B |
$10.96B |
22.24% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$143.942B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
